|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 265.10 EUR | +2.12% |
|
+4.25% | +12.81% |
| 07-03 | Berenberg Updates Price Target, Estimates for UCB on Recent Pipeline Deals | MT |
| 06-25 | US prices for new drugs fell in 2025 as fewer costly gene therapies were launched | RE |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
Cash or Net Debt
- Stock Market
- Stocks
- UCB Stock
- UNC Stock
- Consensus UCB
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
